Equities Analysts Set Expectations for REGENXBIO Q1 Earnings

REGENXBIO Inc. (NASDAQ:RGNX) – Equities researchers at HC Wainwright raised their Q1 2025 earnings estimates for shares of REGENXBIO in a report issued on Monday, March 17th. HC Wainwright analyst Y. Chen now forecasts that the biotechnology company will post earnings per share of ($1.21) for the quarter, up from their previous forecast of ($1.35). HC Wainwright has a “Buy” rating and a $34.00 price target on the stock. The consensus estimate for REGENXBIO’s current full-year earnings is ($4.84) per share. HC Wainwright also issued estimates for REGENXBIO’s Q2 2025 earnings at ($1.20) EPS, Q3 2025 earnings at ($1.20) EPS, Q4 2025 earnings at ($1.19) EPS and FY2025 earnings at ($4.80) EPS.

RGNX has been the topic of a number of other reports. The Goldman Sachs Group cut shares of REGENXBIO from a “buy” rating to a “neutral” rating and cut their price objective for the company from $38.00 to $14.00 in a research note on Tuesday, February 11th. Royal Bank of Canada restated an “outperform” rating and set a $30.00 price target on shares of REGENXBIO in a research report on Tuesday, January 21st. Chardan Capital reiterated a “buy” rating and set a $52.00 price objective on shares of REGENXBIO in a research note on Friday, March 14th. Raymond James began coverage on REGENXBIO in a research report on Friday, February 7th. They issued an “outperform” rating and a $27.00 target price for the company. Finally, Morgan Stanley lifted their price target on REGENXBIO from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Friday, March 14th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.88.

REGENXBIO Price Performance

Shares of REGENXBIO stock opened at $7.80 on Wednesday. REGENXBIO has a 1-year low of $5.62 and a 1-year high of $23.14. The business’s fifty day moving average price is $7.28 and its two-hundred day moving average price is $8.94. The company has a market capitalization of $386.45 million, a P/E ratio of -1.55 and a beta of 1.35.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.27) by $0.26. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. The company had revenue of $21.21 million for the quarter, compared to analysts’ expectations of $23.70 million.

Institutional Investors Weigh In On REGENXBIO

Several large investors have recently modified their holdings of the stock. Alpine Global Management LLC purchased a new stake in shares of REGENXBIO during the fourth quarter valued at $175,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in REGENXBIO by 9.2% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 72,183 shares of the biotechnology company’s stock valued at $558,000 after buying an additional 6,105 shares in the last quarter. Two Sigma Advisers LP boosted its holdings in shares of REGENXBIO by 164.7% in the fourth quarter. Two Sigma Advisers LP now owns 180,000 shares of the biotechnology company’s stock worth $1,391,000 after buying an additional 112,000 shares during the period. Two Sigma Investments LP increased its position in shares of REGENXBIO by 209.2% in the fourth quarter. Two Sigma Investments LP now owns 389,428 shares of the biotechnology company’s stock worth $3,010,000 after acquiring an additional 263,495 shares in the last quarter. Finally, Rafferty Asset Management LLC raised its holdings in shares of REGENXBIO by 22.4% during the fourth quarter. Rafferty Asset Management LLC now owns 93,821 shares of the biotechnology company’s stock valued at $725,000 after acquiring an additional 17,180 shares during the period. 88.08% of the stock is owned by institutional investors.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.